Apr 1 2010
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research (AACR) to be held April 17-21, 2010 in Washington, D.C.
"The presentations at AACR will highlight data supporting the unique mechanism of action, new potential clinical applications and clinical experience with our lead anti-PS agent bavituximab. This is one of the key oncology conferences of the year and we are pleased to have such diverse data to present," commented Joseph Shan, M.P.H., vice president of clinical and regulatory affairs at Peregrine Pharmaceuticals. "AACR will mark the beginning of a very busy time for Peregrine during which we plan to report new data from four cancer trials of our lead product bavituximab and novel brain cancer agent Cotara® and to initiate two new randomized bavituximab Phase II trials in non-small cell lung cancer."
SOURCE Peregrine Pharmaceuticals, Inc.
Novel antibodies show promise for tumor targeting and RAD51 inhibition